Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer

Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer

Kidney-type glutaminase (GLS) and liver-type glutaminase (GLS2) are dysregulated in many cancers, making them appealing targets for cancer therapy. However, their use as prognostic biomarkers is controversial and remains an active area of cancer research. Here, we performed a systematic multiomic an...

Full description

Bibliographic Details
Main Authors: Subbroto Kumar Saha, S.M. Riazul Islam, M. Abdullah-AL-Wadud, Saiful Islam, Farman Ali, Kyoung Sik Park
Format: Article
Language:English
Published: MDPI AG 2019-03-01
Series:Journal of Clinical Medicine
Subjects:
glutaminase
GLS
GLS2
multiomics
prognostic biomarkers
clinical outcomes
cancer therapy
Online Access:http://www.mdpi.com/2077-0383/8/3/355

Internet

http://www.mdpi.com/2077-0383/8/3/355

Similar Items